Definium Therapeutics (DFTX) Cash from Financing Activities (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Cash from Financing Activities data on file, last reported at $5.3 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 429.84% year-over-year to $5.3 million in Q1 2026; TTM through Mar 2026 was $271.6 million, a 219.69% increase from a year earlier, with the FY2025 full-year figure at $267.3 million, up 5.56% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $5.3 million, down from $245.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for DFTX reached as high as $245.9 million in Q4 2025 and fell as low as -$166000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $35.7 million across 5 years, with a median of $3.8 million in 2024.
• Across the five-year window, Cash from Financing Activities plunged 100.18% in 2022 and soared 28930.36% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $416000.0 in 2022, then surged by 523.32% to $2.6 million in 2023, then soared by 46.82% to $3.8 million in 2024, then surged by 6358.31% to $245.9 million in 2025, then sank by 97.84% to $5.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $5.3 million in Q1 2026, $245.9 million in Q4 2025, and $749000.0 in Q3 2025.